Amylyx Pharmaceuticals

NASDAQ: AMLX
Nasdaq Stock Market
Healthcare Biotechnology
Global Rank
#11895
Country Rank
#2221
Market Cap
708.67 M
Price
7.95
Change (%)
0.50%
Volume
867,617

AMLX's Next Dividend

Next Estimated Amount
$0.42
Next Estimated Pay Date
07/01/2018
Last Amount
$0.42
Last Pay Date
04/02/2018
Dividend Shot Clock Ex-Date: 03/28/2018
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

Amylyx Pharmaceuticals Dividend Chart

*Amounts are shown in the stock exchange currency (USD) for convenience

Amylyx Pharmaceuticals( AMLX) Dividend History

Amylyx Pharmaceuticals (NASDAQ: AMLX) currently pays an annual dividend of $0.00 per share, offering a dividend yield of 16.34%. The next dividend payout date has not been announced.
Ex-Dividend Date Amount Adj. Amount Dividend Yield Pay Date Change (%)
2018 $0.42 $0.42 -30%
03/28/2018 $0.42 $0.42 16.34% 04/02/2018 18%
2017 $0.596 $0.596
12/28/2017 $0.356 $0.356 12.36% 01/02/2018 48%
09/28/2017 $0.241 $0.241 7.30% 10/02/2017
*Amounts are shown in the stock exchange currency (USD) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.